The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
“TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION
Open accessAbstract
In Brief Purpose: The purpose of this study was to analyze long-term outcomes for the treatment of type 3 neovascularization/retinal angiomatous proliferation using a “Treat and Extend” dosing regimen for antivascular endothelial growth factor therapy. Methods: This was a retrospective analysis of visual acuity and optical coherence tomography data of 11 eyes of 10 consecutive patients with newly diagnosed type 3 neovascularization/retinal angiomatous proliferation treated with intravitreal bevacizumab and/or ranibizumab with at least a 12-month follow-up. Three monthly injections were followed by continued treatment at intervals increasing by 2 weeks per visit, to a maximum of 10 weeks, unless clinical or optical coherence tomography evidence of persistent or recurrent fluid was present, in which case, the interval was shortened. Results: Mean baseline Snellen visual acuity was 20/80, improved to 20/40 at 1 month, and was maintained throughout the 36-month period (n = 11 at 12 months, n = 10 at 24 months, and n = 8 at 36 months) (P < 0.04, paired t-test). The mean center point optical coherence tomography thickness decreased from 320 μm to 180–230 μm, and was maintained during the study period (P < 0.02). The mean number of injections was seven in the first year, six in the second year, and seven in the third year. Conclusion: “Treat and Extend” antivascular endothelial growth factor dosing in type 3 neovascularization/retinal angiomatous proliferation delivers promising outcomes at a reduced burden for the patient and health care system compared with monthly and optical coherence tomography-guided dosing regimens. A “Treat and Extend” dosing regimen for intravitreal antivascular endothelial growth factor therapy delivers promising long-term visual and anatomic outcomes in type 3 neovascularization/retinal angiomatous proliferation with a reduced burden for patients and the health care system compared with monthly or optical coherence tomography-guided dosing regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
Cited by
Freund, K. B., Zweifel, S. A., & Engelbert, M. (2010) · Retina · doi:10.1097/iae.0b013e3181e7976b · Cited by 386
Self-citationFreund, K. B., Korobelnik, J.-F., Devenyi, R., Framme, C., Galic, J., Herbert, E., Hoerauf, H., Lanzetta, P., Michels, S., Mitchell, P., et al. (2015) · Retina · doi:10.1097/iae.0000000000000627 · Cited by 283
Self-citationEvaluation of Age-related Macular Degeneration With Optical Coherence Tomography
Keane, P. A., Patel, P. J., Liakopoulos, S., Heussen, F. M., Sadda, S. R., & Tufail, A. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.006 · Cited by 280
Shienbaum, G., Gupta, O. P., Fecarotta, C., Patel, A. H., Kaiser, R. S., & Regillo, C. D. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.011 · Cited by 77
Adrean, S. D., Chaili, S., Ramkumar, H., Pirouz, A., & Grant, S. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.01.012 · Cited by 70
Metadata
- Authors
- ENGELBERT, M., ZWEIFEL, S. A., & FREUND, K. B.
- Venue
- Retina
- Published
- 2009-11
- Volume
- 29
- Issue
- 10
- Pages
- 1424-1431
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2325448373
- Cited by
- 192
- References
- 3
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION. https://app.cochat.ai/papers/10.1097/iae.0b013e3181bfbd46
- The paper
- ENGELBERT, M., ZWEIFEL, S. A., & FREUND, K. B. (2009). “TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION. Retina. https://doi.org/10.1097/iae.0b013e3181bfbd46
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.